Mr. Roberto Pistolesi
Dragotti & Associati S.R.L.
Via Nino Bixio, 7
20129 Milano
Italy
Roberto has an extensive experience both in prosecution and opposition procedures before the EPO, where he has been involved in more than 50 cases before the Opposition Divisions or the Boards of Appeal. He also has a wide expertise in multi-national patent litigations, having been involved in several litigations both in Italy and abroad (mainly USA, UK, Germany and France). In particular, he has been involved in patent litigations concerning the following active principles: alendronic acid, atorvastatin, cefaclor, citalopram, docetaxel, enoxaparin,esomeprazole, phosphatidylserine, gabapentin, irbesartan + HCT, latanoprost, olanzapine, omega-3, omeprazole, montelukast, quetiapine, ramipril, repaglinide, rupatadine, salmeterol + fluticasone, and terbinafine. He frequently advises clients on patent strategies and provides infringement and validity opinions.
Roberto has been a technical expert of the Court of Milan since 2002 and of the Court of Venice since 2015, where he assists Judges in patent infringement and/or validity cases.
He was also adjunct Professor at the “Universita’ degli Studi” of Milan from 2011 to 2015, where he taught chemical patent practice to the students of Chemical Science, Industrial Chemistry and Biotechnology.
He has been the Secretary General of FICPI since April 2015. He was the chairman of FICPI’s study and work commission dealing with inventions in the pharma and biotech area from April 2012 to April 2015.
Roberto has an extensive experience both in prosecution and opposition procedures before the EPO, where he has been involved in more than 50 cases before the Opposition Divisions or the Boards of Appeal. He also has a wide expertise in multi-national patent litigations, having been involved in several litigations both in Italy and abroad (mainly USA, UK, Germany and France). In particular, he has been involved in patent litigations concerning the following active principles: alendronic acid, atorvastatin, cefaclor, citalopram, docetaxel, enoxaparin,esomeprazole, phosphatidylserine, gabapentin, irbesartan + HCT, latanoprost, olanzapine, omega-3, omeprazole, montelukast, quetiapine, ramipril, repaglinide, rupatadine, salmeterol + fluticasone, and terbinafine. He frequently advises clients on patent strategies and provides infringement and validity opinions.
Roberto has been a technical expert of the Court of Milan since 2002 and of the Court of Venice since 2015, where he assists Judges in patent infringement and/or validity cases.
He was also adjunct Professor at the “Universita’ degli Studi” of Milan from 2011 to 2015, where he taught chemical patent practice to the students of Chemical Science, Industrial Chemistry and Biotechnology.
He has been the Secretary General of FICPI since April 2015. He was the chairman of FICPI’s study and work commission dealing with inventions in the pharma and biotech area from April 2012 to April 2015.
He frequently lectures on intellectual property both in Italy and abroad. He has published several articles on “Il Sole-24 Ore”, “Pharmachem” and “Il Diritto Industriale”; he is co-author of the Italian and European sections of “Biotechnology and Pharmaceutical Patents – Law and Practice”, Wolters Kluwer, 2008 and 2009 editions.
Education
- Degree in Bio-Organic Chemistry (Università degli Studi di Milano)
- CEIPI diploma on patent litigations in Europe
Bar admissions
- Since June 1998: Italian patent agent
- Since September 1999: Italian trademark agent
- Since March 2000: European patent attorney
- Since June 2000:
- Community trademark attorney
Professional Experience
Partner and CEO of Dragotti & Associati.
Roles in FICPI
-
CET 5 Biotechnology and Pharmaceuticals
CET Group 5 is dedicated to following, reporting and providing substantive comments and opinions on emerging issues relating to the patenting and regulatory affairs in the Biotechnology and Pharmaceutical fields.
In addition, CET 5 is closely following developments related to genetic resources and developing requirements for notice on their country of origin. Prominent issues CET 5 addresses regarding patenting in these technological fields include subject matter eligibility, and in particular, the patentability of chemical/biological inventions developed using machines, computer implementation and/or artificial intelligence. CET 5 supports FICPI in its mission to be an international leader promoting patent protection in the biotechnology and pharmaceutical arts.
- Member
Communications Committee
- Ex Officio Member
Bureau
- Secretary General
Advisory Council
- Bureau
Secretariat
- Secretary General
Training & Education Committee
- Ex Officio Member
Webinar Committee